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Abstract
Purpose A randomized controlled trial was conducted to
determine whether pathologic necrosis in response to pre-
operative treatment with uracil–tegafur(UFT) could be used
to identify patients with colorectal cancer most likely to
beneWt from postoperative adjuvant therapy with the drug.
Patients and methods The 152 patients with colorectal
cancer who received preoperative UFT at a dose of 600 mg/
day for at least 10 days were classiWed into two groups
according to the pathologic necrosis in resected tumor spec-
imens: 90% or more necrosis (sensitive) versus less than
90% necrosis (insensitive). After excluding 13 ineligible
patients, the remaining 139 were then randomly assigned to
receive postoperative adjuvant UFT (400 mg/day) for
12 months or no treatment.
Results Preoperative and postoperative UFT produced no
serious toxicity in any of the patients. Among the 22
patients with sensitive tumors, overall survival was signiW-
cantly better in the UFT group (n = 12) than in the control
(n = 10) (100 vs. 70.0%; P = 0.023). Among the 117
patients with insensitive tumors, there was no signiWcant
diVerence between the two groups (n = 60, 68.1% vs.
n = 57, 76.6%; P = 0.373).
Conclusion Our method involving neoadjuvant UFT can
identify patients most likely to beneWt from postoperative
UFT, as well as those unlikely to beneWt from such treatment.
Keywords Colorectal cancer · Preoperative 
chemotherapy · Pathologic necrosis · UFT
Introduction
Despite the recent development of drugs such as irinotecan,
oxaliplatin, bevacitumab and cetuximab, 5-Xuorouracil (5-
FU) continues to have an important role in the management
of advanced colorectal cancer (Douillard et al. 2000; Blei-
berg 1998; Punt 1998). Uracil–tegafur (UFT) is a prepara-
tion combining uracil and tegafur in a Wxed molar ratio of
4:1 (Fujii et al. 1979). Uracil competitively blocks the
metabolism of 5-FU, leading to increased 5-FU concentra-
tions in plasma and tumor (Ikenaka et al. 1979). UFT can
be administered orally on an outpatient basis. However, the
clinical response of individual tumors to UFT is often
unpredictable. Previous studies have shown that “patho-
logic necrosis” induced by neoadjuvant therapy is the most
reliable determinant of survival in patients with malignant
bone tumors and soft tissue sarcomas (Picci et al. 1997; Eil-
ber et al. 2001).
We conducted a randomized controlled trial to determine
whether pathologic necrosis in response to preoperative
treatment with UFT could be used to identify patients with
colorectal cancer most likely to beneWt from postoperative
adjuvant therapy with the drug.
Patients and methods
Eligibility criteria
To be eligible for the study, patients had to have histologi-
cally proven adenocarcinoma of the colon or rectum, clini-
cally curative resectable, an age of 75 years or younger,
previously received no other cancer treatment, adequate
organ function (a leukocyte count of at least the lower limit
of 3,000/mm3, a platelet count of at least 100,000/mm3,
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1320 J Cancer Res Clin Oncol (2008) 134:1319–1323a total bilirubin level of no more than 1.5 mg/dl, aspartate
aminotaransferase and alanine aminotransferase levels of
no more than 2.5£ the upper limit of normal, and a serum
creatinine level of no more than the upper limit of normal),
and written informed consent.
Preoperative treatment
By outpatient treatment, UFT was given in an oral dose of
600 mg/day (200 mg, every 8 h) for 10 days just before the
day of surgery.
Histopathologic assessment
Resected tumors were stained with hematoxylin and eosin.
Two pathologists independently assessed pathologic necro-
sis. To rule out spontaneous necrosis, we deWned UFT-
induced pathologic necrosis as necrosis of at least 90% of a
cross-section of the tumor center. This cutoV value was
assigned from our previous study. In that study, 126
patients with colorectal cancer were also preoperatively
treated by UFT. By histopathologic assessment, no necro-
sis, less than 50% tumor necrosis, 50% or over and less
than 90% tumor necrosis, and 90% or over tumor necrosis
were seen in 18% (23/126), 39% (49/126), 20% (25/126),
and 28% (28/126) of patients, respectively (Fig. 1a–d). On
the other hand, in the assessment of 48 of the non-UFT
treated patients, no spontaneous necrosis, less than 50%
spontaneous necrosis, 50% or over and less than 90%
necrosis, and 90% or over necrosis were seen in 48% (23/
48), 31% (15/48), 21% (10/48) and 0% (0/48) patients,
respectively (Table 1). By these results, we employed 90%
or over tumor necrosis as an appropriate cutoV value to
avoid spontaneous necrosis of colorectal cancer.
Study design
The patients were divided into two groups according to the
rate of tumor necrosis in response to preoperative UFT:
those with 90% or greater pathologic necrosis (sensitive)
and those with less than 90% pathologic necrosis (insensi-
tive). The patients were then randomly assigned according
to a permuted-block scheme to receive UFT (400 mg/day,
for 12 months) or no treatment (control) after surgery.
The primary endpoint was overall survival, and the sec-
ondary endpoint was relapse-free survival.
Statistical methods
The sample size was based on comparisons of 5-year sur-
vival rates. For the sensitive group, 40 patients were needed
to detect a 35% diVerence in 5-year survival rates (from 60
to 95%) at 5% type I error and 80% power. Because our
previous study (Fujii et al. 2000) showed that colorectal
tumors were sensitive to preoperative UFT in about 28 of
126 patients (22.2%), the planned sample size was 160
patients. Data were analyzed according to intention to treat.
Both survival curves were generated by the Kaplan–Meier
method and compared by the log-rank test. For the patient’s
characteristics, Chi-square test was used excepting age for
which Wilcoxon test was used.
Results
Between 1992 and 1995, we enrolled 152 patients: 78 had
colonic cancer and 74 had rectal cancer. Preoperatively, the
median administered dose of UFT was 7.2 g (range 1.8–
24.6 g). The 13 patients were found to be ineligible because
of histological evidence of non-curative resection (eight
patients), not primary tumor (two), and previous chemo-
therapy (three).
Fig. 1 Histopathologic assessment: resected tumors were stained with
hematoxylin and eosin. a In this case, there was no UFT-induced path-
ologic necrosis at a cross-section of the tumor center. b In this case, tu-
mor necrosis was seen, but this necrosis was less than 50% of the tumor
at a cross-section of the tumor center. c In this case, tumor necrosis was
seen in 90% or over of the tumor at a cross-section of the tumor center.
d In this case, there was no viable cancer cell at a cross-section of the
tumor center. In our previous study, 3 of 126 cases (2.4%) showed
pathologically complete response by preoperative treatment of UFT
Table 1 Tumor necrosis with or without preoperative UFT treatment
0% <50% <90% >90%
UFT treated 
(n = 126)
23 (18.3%) 49 (38.8%) 25 (19.8%) 28 (22.2%)
Control (n = 48) 23 (47.9%) 15 (31.3%) 10 (21%) 0 (0%)123
J Cancer Res Clin Oncol (2008) 134:1319–1323 1321By histopathologic assessment for the 139 eligible
patients, 22 patients (15.8%) were classiWed as having sen-
sitive tumors (postoperative UFT 12, no adjuvant therapy
10) and 117 (84.2%) as having insensitive tumors (postop-
erative UFT 60, no adjuvant therapy 57) (Fig. 2).
In patient’s characteristics of the sensitive group, the
depth of invasion of the tumor in the UFT group was sig-
niWcantly better than the no adjuvant therapy group
(P = 0.035). There was no signiWcant diVerence in any
other baseline characteristic between the sensitive group
and the insensitive group (Table 2). Preoperative UFT was
associated with no serious toxicity or operative complica-
tions. No grade 3 or 4 toxicity (World Health Organization
criteria) occurred during postoperative treatment with UFT.
No patient was lost to follow-up. The median length of
follow-up after surgery was 5.5 years (0.6–9.9). Among the
patients with sensitive tumors, overall survival was signiW-
cantly better in the UFT group (5-year survival rate 100%)
than in the control group (70.0%, 95% CI 41.6–98.4%)
(P = 0.023) (Fig. 3). Among those with insensitive tumors,
survival was similar in the UFT group (5-year survival rate
68.1%, 95% CI 56.2–79.9) and the control group (76.6%,
65.5–87.8%) (P = 0.373). The rate of relapse-free survival
at 5 years was signiWcantly higher in the UFT group than in
the control group among patients with sensitive tumors
Table 2 Patients’ characteris-











Median (range) 56 (46–65) 57 (40–65) 0.72 58.5 (22–74) 57 (36–74) 0.23
Sex
Male 7 4 0.67 38 31 0.35
Female 5 6 22 26
Location of tumor
8 7 0.87 43 40 0.86
Rectum 4 3 17 17
Depth of invasiona
m, sm 0 0 0.04 5 5 1.00
mp 7 1 7 7
ss, se, a1, a2 5 7 47 44
si, ai 0 2 1 1
Lymphnode metastasis
n0 7 2 0.07 38 33 0.55
n1¡3 5 8 22 24
Dukes
A 5 0 0.08 10 10 0.69
B 2 1 28 21
C 5 8 21 24
D 0 1 1 2
Histologic diVerentiation
Well 5 3 0.49 22 15 0.28
Moderately 6 7 37 42
Mucinous 1 0 1 0
a According to general rules for 
clinical and pathological studies 
on cancer of the colon, rectum, 
and anus
b Chi-square test except for age 
with Wilcoxon test
Fig. 2 Trial proWle: 152 patients were enrolled in the trial, and 13
patients were found to be ineligible. On histopathologic assessment,
22 patients were classiWed as having sensitive tumors (postoperative
UFT 12, no adjuvant therapy 10) and 117 (84.2%) as having insensitive
tumors (postoperative UFT 60, no adjuvant therapy 57)
152 enrolled
139 eligible





10 no adjuvant 57 no adjuvant  
13 ineligible123
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similar among those with insensitive tumors (61.4%, 95%
CI 49.1–73.8% vs. 66.4%, 95% CI 54.1–78.7%)
(P = 0.632) (Fig. 4).
Among patients who received UFT postoperatively, the
relative risk for death was 0.0002 (95% CI 0.0001–0.691,
P = 0.010) in the sensitive group, as compared with 1.173
in the insensitive group (95% CI 0.828–1.689, P = 0.371).
Discussion
Our randomized controlled study showed that assessment
of pathologic necrosis in response to preoperative treatment
with UFT can identify patients with colorectal cancer most
likely to beneWt from postoperative treatment with UFT, as
well as those unlikely to beneWt from such treatment.
UFT is commercially available since 1983 in Japan for
gastric, colorectal, pancreas, breast, and lung carcinomas. A
response rate of UFT for colorectal carcinoma is around
20% (Ota et al. 1988). UFT is commonly used for an adju-
vant setting for curatively resected colorectal carcinoma
without any evidence, by large randomized controlled stud-
ies in Japan when we started conducting this trial in 1992.
Recently, the Wnal results of randomized trials by the Japa-
nese National Surgical Adjuvant Study of Colorectal Can-
cer (NSAS-CC) for adjuvant chemotherapy with UFT
comparing surgery alone for stage III colorectal cancer was
reported (Hamaguchi 2007). As the results show, there is
signiWcantly better relapse-free survival (RFS) in rectal
cancer [5-year RFS UFT 68.9%, surgery alone 56.3%, haz-
ard ratio = 0.66 (0.45–0.97), P = 0.0325]; however, there is
no signiWcantly better RFS in colon cancer [5-year RFS
UFT 71.3%, surgery alone 69.6%, hazard ratio = 0.89
(0.60–1.32), P = 0.5586]. Then, there is still no evidence of
the beneWt of adjuvant UFT for colon cancer in Japan. We
suppose that the reason for this negative impact is mainly
the low power of the anti-tumor eVect of UFT on colon can-
cer, showing that the cancer was not chemosensitive to
UFT.
In our study, 5-year survival and relapse-free survival
rates of the control group in sensitive tumors (70, 60%)
seemed to be poorer than those in insensitive tumors (76.6,
66.4%). We speculate that these results were because,
tumors with higher activity of cell division were sensitive
to chemotherapy, but tumor progression of these tumors
was faster than those with lower activity.
Because we employed a high cutoV value for pathologic
necrosis to eliminate spontaneous necrosis, 18% of the
patients who received preoperative oral UFT were pre-
Fig. 3 Overall survival: among 
the 22 patients with sensitive tu-
mors, 5-year survival rate was 
signiWcantly better in the UFT 
group (100%) than in the control 
group (70.0%) (P = 0.023). 
Among 117 patients with insen-
sitive tumors, 5-year survival 
rate was similar in the UFT 
group (68.1%) and the control 
group (76.6%) (P = 0.373)
Number at risk
UFT group      12     12             11              10 3 0
Control group 10     10              7                7 1 0
Number at risk
UFT group      60    58              51             40 5                1
Control group 57    53 47 42              7                2






































Fig. 4 Relapse free survival: 
among the 22 patients with sen-
sitive tumors, 5-year relapse free 
survival rate was signiWcantly 
better in the UFT group (100%) 
than in the control group 
(60.0%) (P = 0.009). Among 
117 patients with insensitive 
tumors, 5-year relapse free sur-
vival rate was similar in the UFT 
group (61.4%) and control group 
(66.4%) (P = 0.632)
Number at risk
UFT group      60    54              49              45 6                2
Control group 57    51 43 38               7                3
Number at risk
UFT group      12    12              12              11 4                1







































J Cancer Res Clin Oncol (2008) 134:1319–1323 1323dicted to have UFT-sensitive tumors. This value is similar
to the rate of tumor sensitivity to UFT in the phase II study
of this drug (Ota et al. 1988) and also the conventional
treatment with 5-FU (loading or weekly bolus) in patients
with metastatic colorectal cancer (Thirion et al. 2004).
UFT is now usually combined with leucovorin (LV) for
the treatment of colorectal cancer (Pazdur 1997). A
response rate of UFT/LV for advanced colorectal cancer is
42.2%. In our preliminary results for the preoperative use
of UFT/LV, 90% or over necrosis was found in 14 cases in
34 preoperatively UFT/LV treated colorectal patients (sen-
sitive rate of UFT/LV is 37.8%). The recent National Surgi-
cal Adjuvant Breast and Bowel Project (NSABP) adjuvant
colon clinical trial (CO-6), comparing UFT/LV versus
weekly regimen of intravenous 5-Xuorouracil plus LV in
the postoperative adjuvant therapy of Dukes’ B and C colon
cancer patients, reported that there is no signiWcant diVer-
ence of both treatments (Lembersky et al. 2006). We
believe that we can use the same method, used for UFT/LV
adjuvant setting for colorectal cancer patients, for other
agents including Capecitabine, FOLFOX, and FOLFIRI
(Goldberg et al. 2004; Tournigand et al. 2004).
We conclude that pathologic tumor necrosis in response
to preoperative UFT can be used to predict the response of
colorectal tumors to postoperative adjuvant therapy with
UFT. Patients whose tumors are insensitive to preoperative
UFT should be given irinotecan or oxaliplatin as Wrst-line
chemotherapy in the event of recurrence. Our method is
practical (requiring only routine pathologic examination),
inexpensive, and highly predictable.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which
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